Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?
作者信息
Efird Jimmy T, Jindal Charulata, Fitzgerald Timothy, Biswas Tithi
机构信息
Center for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Surgical Oncology, Maine Medical Center Cancer Institute, Scarborough, Maine, USA.
出版信息
Transl Gastroenterol Hepatol. 2018 Sep 7;3:58. doi: 10.21037/tgh.2018.08.06. eCollection 2018.
Abstract
摘要
相似文献
1
Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?氟尿嘧啶、亚叶酸钙和奥沙利铂联合或不联合奥那珠单抗治疗表皮生长因子受体-2阴性、间质-上皮转化阳性胃食管腺癌的疗效：这真的是失败吗？
Transl Gastroenterol Hepatol. 2018 Sep 7;3:58. doi: 10.21037/tgh.2018.08.06. eCollection 2018.
2
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.一项关于FOLFOX联合或不联合MET抑制剂奥那珠单抗治疗晚期胃及胃食管交界腺癌的随机II期研究。
Oncologist. 2016 Sep;21(9):1085-90. doi: 10.1634/theoncologist.2016-0038. Epub 2016 Jul 8.
3
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.FOLFOX 单药或联合 ri lotumumab 或 panitumumab 一线治疗晚期胃食管腺癌患者（PRODIGE 17-ACCORD 20-MEGA）：一项随机、开放标签、三臂 II 期试验。
Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.
4
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.评价围手术期 UGT1A1 基因型剂量 gFOLFIRINOX 与局部晚期胃食管腺癌患者切缘阴性切除率和病理反应分级的关系：一项 2 期临床试验。
JAMA Netw Open. 2020 Feb 5;3(2):e1921290. doi: 10.1001/jamanetworkopen.2019.21290.
5
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.曲妥珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛作为人表皮生长因子受体 2 阳性局部晚期胃食管腺癌患者的围手术期治疗：一项 Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer 研究组的 II 期试验。
Int J Cancer. 2021 Sep 15;149(6):1322-1331. doi: 10.1002/ijc.33696. Epub 2021 May 29.
6
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.曲妥珠单抗治疗人表皮生长因子受体 2 阳性胃或胃食管结合部转移性腺癌的临床观察。
Oncologist. 2020 Aug;25(8):e1181-e1187. doi: 10.1634/theoncologist.2020-0109. Epub 2020 Jun 4.
7
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.氟尿嘧啶、亚叶酸钙联合奥沙利铂或顺铂用于转移性胃食管腺癌的III期试验：德国内科肿瘤协作组的一项研究
J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378.
8
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.多西他赛、氟尿嘧啶、亚叶酸钙、奥沙利铂（TEF）每两周 1 次作为晚期胃癌和胃食管结合部腺癌的一线治疗：多中心队列的安全性和疗效。
Gastric Cancer. 2014 Apr;17(2):341-7. doi: 10.1007/s10120-013-0266-6. Epub 2013 Jun 6.
9
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.FOLFIRINOX 治疗晚期胃食管交界癌：一项 2 期非随机临床试验。
JAMA Oncol. 2020 Aug 1;6(8):1231-1240. doi: 10.1001/jamaoncol.2020.2020.
10
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).VEGFR-3和CXCR4作为晚期食管胃癌患者接受氟尿嘧啶、亚叶酸钙联合奥沙利铂或顺铂治疗的预测标志物：德国内科肿瘤协作组（AIO）的一项比较研究
BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.
本文引用的文献
1
Gastric cancer: epidemiology, prevention, classification, and treatment.胃癌：流行病学、预防、分类及治疗
Cancer Manag Res. 2018 Feb 7;10:239-248. doi: 10.2147/CMAR.S149619. eCollection 2018.
2
Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with infection.c-Met和肝细胞生长因子在各种胃部病变中的表达及其与感染的关系。
Oncol Lett. 2017 Nov;14(5):6151-6155. doi: 10.3892/ol.2017.6983. Epub 2017 Sep 18.
3
Targeted therapies for gastric cancer: failures and hopes from clinical trials.胃癌的靶向治疗：临床试验中的失败与希望
Oncotarget. 2017 Jan 26;8(34):57654-57669. doi: 10.18632/oncotarget.14825. eCollection 2017 Aug 22.
4
Current status of lymph node micrometastasis in gastric cancer.胃癌中淋巴结微转移的现状
Oncotarget. 2017 Apr 27;8(31):51963-51969. doi: 10.18632/oncotarget.17495. eCollection 2017 Aug 1.
5
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection.MET4表达预示幽门螺杆菌感染的胃癌预后不良。
Cancer Sci. 2017 Mar;108(3):322-330. doi: 10.1111/cas.13146.
7
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.METLung：奥沙利umab 联合厄洛替尼对比厄洛替尼治疗既往治疗的 IIIB 或 IV 期非小细胞肺癌的 III 期随机试验结果
J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.
8
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.氟尿嘧啶、亚叶酸和奥沙利铂联合或不联合奥妥珠单抗治疗人表皮生长因子受体 2（HER2）阴性、间质上皮转化因子（MET）阳性胃食管腺癌的效果：METGastric 随机临床试验。
JAMA Oncol. 2017 May 1;3(5):620-627. doi: 10.1001/jamaoncol.2016.5580.
9
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.一项关于FOLFOX联合或不联合MET抑制剂奥那珠单抗治疗晚期胃及胃食管交界腺癌的随机II期研究。
Oncologist. 2016 Sep;21(9):1085-90. doi: 10.1634/theoncologist.2016-0038. Epub 2016 Jul 8.
10
Helicobacter pylori Diversity and Gastric Cancer Risk.幽门螺杆菌的多样性与胃癌风险
mBio. 2016 Jan 26;7(1):e01869-15. doi: 10.1128/mBio.01869-15.
Zotero 插件